Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 11« First...34567...10...Last »

Med Ad News Announces 2017 Manny Awards Finalists, Person of the Year

Med Ad News announces the 28th Annual Manny Awards nominees; FCB Health CEO/President Dana Maiman named ad industry Person of the Year.

Read More »

Breast cancer drug combo succeeds key study

Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.

Read More »

Nektar’s opioid painkiller succeeds in key study

Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.

Read More »

Cerulean to Slash More Than Half of Its Remaining Staff, Merge With SoCal Biotech

Shares of Cerulean Inc. plunged more than 61 percent this morning after the company announced it was being acquired by privately held Dare Bioscience, and has sold off some of its assets to BlueLink Pharmaceuticals and Novartis.

Read More »

CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects

CytomX Therapeutics and Bristol-Myers Squibb are strengthening their relationship with the expansion of a 2014 collaboration agreement. The companies announced a plan to include up to eight additional targets, six in oncology and two in non-oncology areas, using CytomX’s proprietary Probody platform.

Read More »

China considers ways to speed up time to market for imported drugs

China is considering taking measures that will shorten the time to market for approved imported drugs in an effort to ease a shortage of such medicines, according to the China Food and Drug Administration (CFDA).

Read More »

Newer type 2 diabetes drugs show heart protective quality in study

A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released from a so-called real world study sponsored by AstraZeneca.

Read More »

Amgen cholesterol drug cuts heart attack, stroke risk but shares fall

Amgen Inc,’s Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clinical benefit beyond its ability to slash “bad” LDL cholesterol levels, data from a huge study known as Fourier showed on Friday.

Read More »

Medtronic heart valve replacement succeeds in intermediate-risk patients: study

Medtronic Plc’s non-invasive transcatheter aortic valve replacement (TAVR) system proved as safe as traditional surgery in intermediate-risk patients in a two-year study presented on Friday, paving the way for its use in a wider patient population.

Read More »

Indian drugmakers face squeeze in U.S. healthcare market

India’s small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries.

Read More »

Circassia strikes deal with AstraZeneca for respiratory drugs

Britain’s Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.

Read More »

Biogen Faces Biggest One-Day Drop

In what feels a bit like a self-fulfilling prophecy, two analyst firms downgraded Biogen, causing the stock to drop.

Read More »

Crippled Bay Area Pharma Threshold Rockets on Reverse Merger Deal With Molecular Templates

Shares of Threshold Pharmaceuticals shot up more than 43 percent this morning after the company announced it was merging with Austin, Texas-based Molecular Templates Inc. and receiving an infusion of millions of dollars in financing.

Read More »

FDA Deals Another Blow to AstraZeneca’s Blood Drug

The U.S. Food and Drug Administration gave AstraZeneca’s New Drug Application for ZS-9 (sodium zirconium cyclosiliate) a Complete Response Letter (CRL) — again. The drug was being developed for hyperkalemia by ZS Pharma, a wholly owned subsidiary of AstraZeneca.

Read More »

Get thesis – completely unique job

Get thesis – completely unique job It takes much time to check out the certain matter and find out the needful results. Study paper requirements plenty of expertise to make a good one. This write is creating within the last season of examine and yes it demonstrates all your expertise and abilities.

Read More »

PTC to buy pricey Duchenne drug, signals price change

PTC Therapeutics Inc. said on Thursday it would buy Marathon Pharmaceuticals LLC’s recently approved Duchenne muscular dystrophy drug, Emflaza, and promised to re-examine the hefty U.S. price tag on the treatment.

Read More »

Not A Term Paper Mill!

★Edu★ Your Optimal Success Guide For Research Paper Writing The land of the rising sun has given rise to so many technology related developments that it is really next to impossible to keep pace with. The rates charged should be reasonable in that they reflect the quality of papers.

Read More »

IBM to integrate MedyMatch technology to help spot brain bleeding

Israel’s MedyMatch Technology said on Thursday IBM Watson Health would integrate MedyMatch’s technology into its offerings to imaging experts in hospitals to help doctors identify intracranial bleeding from head trauma and stroke.

Read More »

Major Reorganization to Hit the NIH, Deep Cuts to Affect Thousands Under Trump Budget Plan

Federal spending on health and human services takes a major blow under the first federal spending plan proposed by President Donald Trump.

Read More »

European Approval for Label Extension of Cinryze

The European Commission approved a label extension for three new indications for Shire’s Cinryze, broadening its use to children with hereditary angioedema.

Read More »

Page 5 of 11« First...34567...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation